Stevanato Group S.p.A. (STVN)
NYSE: STVN · Real-Time Price · USD
25.12
+0.41 (1.66%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.

It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services.

It also provides contract development and manufacturing services for customer-owned drug delivery devices.

The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug product, glass packaging, and fill and finish contract manufacturers.

The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.

Stevanato Group S.p.A.
Stevanato Group logo
CountryItaly
Founded1949
IPO DateJul 16, 2021
IndustryMedical Instruments & Supplies
SectorHealthcare
Employees5,521
CEOFranco Stevanato

Contact Details

Address:
Via Molinella 17
Piombino Dese, PD 35017
Italy
Phone39 04 99 31 811
Websitestevanatogroup.com

Stock Details

Ticker SymbolSTVN
ExchangeNYSE
Fiscal YearJanuary - December
Reporting CurrencyEUR
IPO Price$21.00
CIK Code0001849853
CUSIP NumberT9224W109
ISIN NumberIT0005452658
SIC Code3841

Key Executives

NamePosition
Franco StevanatoChief Executive Officer and Executive Chairman
Marco Dal LagoChief Financial Officer
Ugo GayChief Operations Officer
Lisa MilesChief Communications and Investor Relations Officer
Paolo De FabritiisChief Human Resources Officer
Mauro StocchiChief Business Strategy Officer
Riccardo ButtaPresident of Americas

Latest SEC Filings

DateTypeTitle
Jun 12, 2025S-8 POSSecurities to be offered to employees in employee benefit plans, post-effective amendments
Jun 11, 2025144Filing
Jun 10, 20256-KReport of foreign issuer
Jun 5, 2025SDForm - SD
May 13, 20256-KReport of foreign issuer
May 8, 20256-KReport of foreign issuer
May 8, 20256-KReport of foreign issuer
May 8, 20256-KReport of foreign issuer
May 2, 20256-KReport of foreign issuer
Mar 14, 20256-KReport of foreign issuer